Tags

Type your tag names separated by a space and hit enter

A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis.
Clin Vaccine Immunol. 2014 May; 21(5):747-54.CV

Abstract

The environmental Gram-negative encapsulated bacillus Burkholderia pseudomallei is the causative agent of melioidosis, a disease associated with high morbidity and mortality rates in areas of Southeast Asia and northern Australia in which the disease is endemic. B. pseudomallei is also classified as a tier I select agent due to the high level of lethality of the bacterium and its innate resistance to antibiotics, as well as the lack of an effective vaccine. Gram-negative bacteria, including B. pseudomallei, secrete outer membrane vesicles (OMVs) which are enriched with multiple protein, lipid, and polysaccharide antigens. Previously, we demonstrated that immunization with multivalent B. pseudomallei-derived OMVs protects highly susceptible BALB/c mice against an otherwise lethal aerosol challenge. In this work, we evaluated the protective efficacy of OMV immunization against intraperitoneal challenge with a heterologous strain because systemic infection with phenotypically diverse environmental B. pseudomallei strains poses another hazard and a challenge to vaccine development. We demonstrated that B. pseudomallei OMVs derived from strain 1026b afforded significant protection against septicemic infection with B. pseudomallei strain K96243. OMV immunization induced robust OMV-, lipopolysaccharide-, and capsular polysaccharide-specific serum IgG (IgG1, IgG2a, and IgG3) and IgM antibody responses. OMV-immune serum promoted bacterial killing in vitro, and passive transfer of B. pseudomallei OMV immune sera protected naive mice against a subsequent challenge. These results indicate that OMV immunization provides antibody-mediated protection against acute, rapidly lethal sepsis in mice. B. pseudomallei-derived OMVs may represent an efficacious multivalent vaccine strategy against melioidosis.

Authors+Show Affiliations

Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

24671550

Citation

Nieves, Wildaliz, et al. "A Burkholderia Pseudomallei Outer Membrane Vesicle Vaccine Provides Protection Against Lethal Sepsis." Clinical and Vaccine Immunology : CVI, vol. 21, no. 5, 2014, pp. 747-54.
Nieves W, Petersen H, Judy BM, et al. A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis. Clin Vaccine Immunol. 2014;21(5):747-54.
Nieves, W., Petersen, H., Judy, B. M., Blumentritt, C. A., Russell-Lodrigue, K., Roy, C. J., Torres, A. G., & Morici, L. A. (2014). A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis. Clinical and Vaccine Immunology : CVI, 21(5), 747-54. https://doi.org/10.1128/CVI.00119-14
Nieves W, et al. A Burkholderia Pseudomallei Outer Membrane Vesicle Vaccine Provides Protection Against Lethal Sepsis. Clin Vaccine Immunol. 2014;21(5):747-54. PubMed PMID: 24671550.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis. AU - Nieves,Wildaliz, AU - Petersen,Hailey, AU - Judy,Barbara M, AU - Blumentritt,Carla A, AU - Russell-Lodrigue,Kasi, AU - Roy,Chad J, AU - Torres,Alfredo G, AU - Morici,Lisa A, Y1 - 2014/03/26/ PY - 2014/3/28/entrez PY - 2014/3/29/pubmed PY - 2014/12/23/medline SP - 747 EP - 54 JF - Clinical and vaccine immunology : CVI JO - Clin Vaccine Immunol VL - 21 IS - 5 N2 - The environmental Gram-negative encapsulated bacillus Burkholderia pseudomallei is the causative agent of melioidosis, a disease associated with high morbidity and mortality rates in areas of Southeast Asia and northern Australia in which the disease is endemic. B. pseudomallei is also classified as a tier I select agent due to the high level of lethality of the bacterium and its innate resistance to antibiotics, as well as the lack of an effective vaccine. Gram-negative bacteria, including B. pseudomallei, secrete outer membrane vesicles (OMVs) which are enriched with multiple protein, lipid, and polysaccharide antigens. Previously, we demonstrated that immunization with multivalent B. pseudomallei-derived OMVs protects highly susceptible BALB/c mice against an otherwise lethal aerosol challenge. In this work, we evaluated the protective efficacy of OMV immunization against intraperitoneal challenge with a heterologous strain because systemic infection with phenotypically diverse environmental B. pseudomallei strains poses another hazard and a challenge to vaccine development. We demonstrated that B. pseudomallei OMVs derived from strain 1026b afforded significant protection against septicemic infection with B. pseudomallei strain K96243. OMV immunization induced robust OMV-, lipopolysaccharide-, and capsular polysaccharide-specific serum IgG (IgG1, IgG2a, and IgG3) and IgM antibody responses. OMV-immune serum promoted bacterial killing in vitro, and passive transfer of B. pseudomallei OMV immune sera protected naive mice against a subsequent challenge. These results indicate that OMV immunization provides antibody-mediated protection against acute, rapidly lethal sepsis in mice. B. pseudomallei-derived OMVs may represent an efficacious multivalent vaccine strategy against melioidosis. SN - 1556-679X UR - https://www.unboundmedicine.com/medline/citation/24671550/A_Burkholderia_pseudomallei_outer_membrane_vesicle_vaccine_provides_protection_against_lethal_sepsis_ L2 - https://journals.asm.org/doi/10.1128/CVI.00119-14?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -